• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Emcure Pharmaceuticals Limited — Board Meeting, 04-02-2026: Outcome of Board Meeting

    04-02-2026 | 01:34 pm

    Emcure's board approved Q3 results: Consolidated Revenue hit ₹2,363 Cr (+20.4% YoY) and PAT ₹231 Cr (+48.2% YoY). The company appointed a new Company Secretary and approved re-appointing three Independent Directors. Strategic moves include the Poviztra® launch & Zuventus acquisition.

    No comments yet. Be the first to comment!

    All announcements from Emcure Pharmaceuticals Limited